| 前收市價 | 7.98 |
| 開市 | 7.64 |
| 買盤 | 8.40 x 100 |
| 賣出價 | 8.58 x 200 |
| 今日波幅 | 7.44 - 8.78 |
| 52 週波幅 | 0.66 - 11.40 |
| 成交量 | |
| 平均成交量 | 5,513,383 |
| 市值 | 250.041M |
| Beta 值 (5 年，每月) | 0.92 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -1.31 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 11.00 |
ZacksCandel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
Candel (CADL) rallies 43% as the FDA grants the orphan drug designation to its lead candidate, CAN-2409, for treating non-metastatic pancreatic cancer.
ZacksCandel (CADL) Up on Upbeat Data From Pancreatic Cancer Study
Candel's (CADL) CAN-2409 demonstrates improvements in estimated median overall survival versus the control group in treating borderline resectable pancreatic ductal adenorcarcinoma. The stock rises.
BenzingaAfter Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study
Thursday, Candel Therapeutics Inc (NASDAQ:CADL) released updated interim survival data from the ongoing phase 2 trial of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection for borderline resectable pancreatic ductal adenocarcinoma. Survival data were updated with eight months of further follow-up since the first analysis was presented at the 2023 Society for Immunotherapy Annual Meeting. Also Read: Micro-Cap Cancer Focused Candel Ther
